Lupin has informed that it enclosed a Press Release as regards the Company having entered into a first partnership with Shenzhen Foncoo Pharmaceutical Co. which reinforces its commitment to bringing high quality generic and complex generic medicines to patients around the world. This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.